Phenomic AI
Toronto, CA · Founded 2017 · 14 employees on LinkedIn · 8 known investors
Find your way into Phenomic AI
479 people in our graph share verified history with the Phenomic AI team — schools, employers, funds. One of them is your warm intro.
Deji Sasegbonunlockedknows Sam Cooper · together at Imperial College London (overlapped)
×5knows the team · via University of Toronto
×5knows the team · via Imperial College London
knows the team · via The Institute of Cancer Research, U. of London
Phenomic AI is a biotech company developing therapies for solid tumors using a machine-learning-powered transcriptomics platform that analyzes single-cell RNA data to identify drug targets and understand tumor biology. The company develops antibody-based therapies informed by its analysis of cell-cell interactions in tumor microenvironments, with current programs targeting stromal and immune components of difficult-to-treat cancers.
Founders & leadership
Phenomic AI was founded in 2017 by Sam Cooper and Oren Kraus.
SC
Sam CooperinCo-founder & CTOSam Cooper holds a PhD in Computational Medicine from Imperial College London, where he studied cancer biology under Robert Glen and Chris Bakal. He is co-founder and CTO of Phenomic AI, where he led development of single-cell RNA sequencing datasets for solid tumors and contributed to identifying drug targets now advancing in clinical development.
OK
Oren KrausinCo-founderOren Kraus completed a BASc and MASc in mechanical engineering at the University of Toronto, where he later earned a PhD under Brendan Frey studying deep learning applications to microscopy image analysis. He co-founded Phenomic AI based on this research, and previously led machine learning teams at ProteinQure and Recursion.
Investors · 8
Cantos Ventures✓ verifiedSan Francisco · $400K – $1.5M
AV8 VenturesPalo Alto · $500K – $10M
CTI Life Sciences Fund L.P.Montréal
Garage CapitalWaterloo
Hemi Ventures, LlcPalo Alto · $250K – $500Kvia Amy Gu · inferred
Toronto Innovation Acceleration PartnersToronto
Hike VenturesreportedSan Francisco · $1M – $5M
Radical VenturesreportedToronto · $1M – $25M
Funding
SEC filings, press & company announcements- Undisclosed amountSeedDec 2020Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 5
by search overlap
Phinomics20 shared keywordsPhinomics is a cancer drug discovery platform that captures extrachromosomal circular DNA (the "Circulome") at high resolution from matched tumor and normal patient samples, integrating it with DNA, RNA, epigenetics, and proteomics into a multi-omic knowledge graph. It applies explainable AI to this data to identify novel therapeutic targets, resistance mechanisms, and patient stratification biomarkers for oncology therapeutics development.
Predictive Oncology19 shared keywordsPredictive Oncology develops drug discovery solutions for biopharma companies that combine artificial intelligence with a proprietary biobank of over 150,000 tumor samples to accelerate oncology drug development and improve therapeutic outcomes for cancer patients.
Genomics Plc18 shared keywordsGenomics builds a genotype-phenotype database and genetic risk-prediction tools used to support pharmaceutical drug discovery and clinical trials, as well as population health management and clinical decision support for healthcare providers. It serves life sciences companies and healthcare systems through its Life Sciences and Health & Wellness divisions.
Tagomics15 shared keywordsTagomics develops multimodal technologies for precision medicine and next-generation diagnostics. The company is based in Cambridge and focuses on improving patient outcomes through advanced diagnostic technologies.
Nomic Bio14 shared keywordsNomic offers an end-to-end protein profiling service built on its nELISA technology, quantifying up to 1000 informative proteins with absolute quantification for research studies. It targets researchers doing proteomics work, aiming for high-throughput, low-cost profiling in the biotech and life sciences market.
Companies competing with Phenomic AI for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Phenomic AI do?
- Phenomic AI is a biotech company developing therapies for solid tumors using a machine-learning-powered transcriptomics platform that analyzes single-cell RNA data to identify drug targets and understand tumor biology. The company develops antibody-based therapies informed by its analysis of cell-cell interactions in tumor microenvironments, with current programs targeting stromal and immune components of difficult-to-treat cancers.
- Who founded Phenomic AI?
- Phenomic AI was founded by Sam Cooper, Oren Kraus in 2017.
- Who are Phenomic AI's investors?
- Phenomic AI's investors include Cantos Ventures, AV8 Ventures, CTI Life Sciences Fund L.P., Garage Capital, Hemi Ventures, Llc, Toronto Innovation Acceleration Partners, Hike Ventures, Radical Ventures.
- Where is Phenomic AI headquartered?
- Phenomic AI is headquartered in Toronto, CA.